ā”Hetero announces interim clinical results of Molnupriavir
By IANS
In April this year, Hetero had entered into a non-exclusive licensing agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., the US, to manufacture and supply Molnupiravir in India and over 100 low and middle-income countries (LMICs).